Pancreatic endocrine tumors

Mansour, John C.; Chen, Herbert

doi:10.1016/j.jss.2003.12.007

Cited by 137 publications

(98 citation statements)

References 180 publications

(214 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnosis is confirmed by the demonstration of inappropriately elevated insulin and proinsulin levels associated with serum glucose values of less than 50 mg/dL during 48 hour fast period. 3,4 Insulinoma may be associated with a hereditary syndrome in nearly 10% of patients, the most common being multiple endocrine neoplasia type 1 (MEN1) 5 . Insulinomas are evenly distributed throughout the pancreas and are usually less than 2 cm in size in approximately 90% of cases 1 .…”

Section: Introductionmentioning

confidence: 99%

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Nockel

Babic

Millo

et al. 2016

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context. The reliable localization of insulinoma is critical for the successful surgical treatment.Objective. This study compared the accuracy of 68 Gallium (Ga)-DOTATATE PET/CT to anatomic imaging modalities, selective arterial secretagogue injection (SASI), and intraoperative ultrasound (IOUS) and palpation for localizing insulinoma in patients who were biochemically cured. Design, Setting, and Patients. We conducted a retrospective analysis of 31 patients who had an insulinoma confirmed on histology and were biochemically cured. The results of CT, MRI, transabdominal US, IOUS, 68 Ga-DOTATATE PET/CT, SASI, and operative findings were analyzed. Intervention, Main Outcome Measures, Results: The insulinomas were correctly localized in 17 out of 31 (55%) of patients by CT, in 17 out of 28 (61%) by MRI, in 6 out of 28 (21%) by US, and in 9 out of 10 (90%) by 68 Ga-DOTATATE. IOUS was performed in 31 patients, and 29 of them had an insulinoma successfully localized (93.5%). Thirty patients underwent SASI, and the insulinoma was regionalized in 28 out of 30 patients (93%). In 19 out of 23 patients (83%), manual palpation identified insulinoma. In patients who had all four noninvasive imaging studies, CT was concordant with 68 Ga-DOTATATE in 6 out of 9 patients (67%); MRI in 8 out of 9 (78%); US in 0 out of 9; and in 1 out of 9 patients (11%) the lesion was only seen by 68 Ga-DOTATATE. Conclusions:68 Ga-DOTATATE PET/CT identifies most insulinomas and may be considered as an adjunct imaging study when all imaging studies are negative and when a minimally invasive surgical approach is planned.PRECIS: We studied 68Ga-DOTATATE PET/CT imaging in patients with insulinoma and found it identifies most tumors and should be considered as an adjunct imaging study.

show abstract

Section: Introductionmentioning

confidence: 99%

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Nockel

Babic

Millo

et al. 2016

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

“…The overall prognosis and long-term survival for PNET patients are far better than for patients with exocrine pancreatic cancer [13,14]. The overall 5-year survival rate is in the range of 30% in NF-PNETs to 97% in insulinoma, one category of F-PNET [15].…”

Section: Introductionmentioning

confidence: 99%

Neuroendocrine Tumors of the Pancreas

et al. 2009

View full text Add to dashboard Cite

show abstract

“…PETs occur in adults of all age groups, with no sex differences (prevalence of w1 in 100 000 individuals) and are extremely rare in children. PETs may be isolated or occur in association with other endocrine tumours in the multiple endocrine neoplasia type 1 (MEN-1) syndrome or, more rarely, in the von Hippel-Lindau syndrome (Mansour & Chen 2004, Oberg & Eriksson 2005. PETs, like all NETs, are categorized on the basis of their clinical manifestations into functioning and non-functioning tumours.…”

Section: Introductionmentioning

confidence: 99%

Cytological Ki-67 in pancreatic endocrine tumours: an opportunity for pre-operative grading

Piani¹,

Franchi²,

Cappelletti³

et al. 2008

Endocrine Related Cancer

View full text Add to dashboard Cite

The cytological Ki-67 expression measured on cytological samples collected by endoscopic ultrasonography-guided fine needle aspiration cytology (EUS-FNAC) may provide pre-operative indications for pancreatic endocrine tumours (PETs) management. The aim of our study was to assess reliability of Ki-67 expression measured on cytological samples obtained by EUS-FNAC in patients with PETs. Eighteen patients with PETs underwent EUS-FNAC before surgery. Ki-67 expression was measured on FNACs and on histological sections. Using a cut-off of 2%, percent agreement of Ki-67 expression on cytological and histological samples was 89% (k-statistic: 0.78, 95% confidence intervals (95% CI): 0.5, 1.0). Using cut-off values of 2 and 10%, percent agreement was 78% (k-statistic: 0.65, 95% CI: 0.3, 0.9). Ki-67 expression measured on cytological samples obtained by EUS-FNAC before surgery showed good agreement with that measured on histological samples.

show abstract

Pancreatic endocrine tumors

Cited by 137 publications

References 180 publications

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Neuroendocrine Tumors of the Pancreas

Cytological Ki-67 in pancreatic endocrine tumours: an opportunity for pre-operative grading

Contact Info

Product

Resources

About